Scarica l'app Stockscreener
2.86
1.78%
0.05
Dopo l'orario di chiusura:
2.91
0.05
+1.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now? - Insider Monkey
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
5 Best Fundamentally Strong Penny Stocks to Invest In Now - Insider Monkey
MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MannKind sets May 6 earnings release, 4:30 p.m. webcast - Stock Titan
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
MNKD Maintained by Wells Fargo -- Price Target Raised to $8.00 - GuruFocus
MannKind (NASDAQ:MNKD) Trading Up 5.5% Following Analyst Upgrade - MarketBeat
Wells Fargo & Company Boosts MannKind (NASDAQ:MNKD) Price Target to $8.00 - MarketBeat
HC Wainwright Estimates MannKind's Q1 Earnings (NASDAQ:MNKD) - MarketBeat
MannKind (MNKD) CFO has shares withheld for RSU tax obligations - Stock Titan
FY2027 EPS Estimates for MannKind Reduced by HC Wainwright - MarketBeat
How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty - Yahoo Finance
Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential - Insider Monkey
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
5 Stocks Under $5 with Huge Upside Potential - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 29.8% in March - MarketBeat
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MNKD Maintains Rating by Mizuho -- Price Target Lowered to $8.00 - GuruFocus
Leerink reiterates Outperform on MannKind stock, sees overreaction - Investing.com
Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com - Investing.com UK
Risk Check: Is MannKind Corporation in a bullish channel2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
MannKind (NASDAQ: MNKD) details 2026 virtual meeting, board elections and pay vote - Stock Titan
[ARS] MANNKIND CORP SEC Filing - Stock Titan
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
Q4 2025 MannKind Corp Earnings Call Transcript - GuruFocus
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Q2 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Truist reiterates MannKind stock rating on partner trial data By Investing.com - Investing.com India
Truist reiterates MannKind stock rating on partner trial data - Investing.com
MannKind Corporation $MNKD Shares Bought by JPMorgan Chase & Co. - MarketBeat
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? - Insider Monkey
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A - Stock Titan
MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan
MannKind (MNKD) awards performance RSUs and stock options to officer - Stock Titan
Setup Watch: Is now the right time to enter MannKind CorporationTrend Reversal & Smart Allocation Stock Reports - baoquankhu1.vn
How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance
Chart Watch: Whats the beta of MannKind Corporation stockMarket Risk Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure - Markets Mojo
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss - AD HOC NEWS
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's What Happened - MarketBeat
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):